Past-futures in experimental care: breast cancer and HIV medicine
Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developm...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sophie Day [verfasserIn] William Viney [verfasserIn] Jane Bruton [verfasserIn] Helen Ward [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: New Genetics and Society - Taylor & Francis Group, 2023, 40(2021), 4, Seite 449-472 |
|---|---|
| Übergeordnetes Werk: |
volume:40 ; year:2021 ; number:4 ; pages:449-472 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.1080/14636778.2020.1861542 |
|---|
| Katalog-ID: |
DOAJ099470578 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ099470578 | ||
| 003 | DE-627 | ||
| 005 | 20240414034738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240414s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14636778.2020.1861542 |2 doi | |
| 035 | |a (DE-627)DOAJ099470578 | ||
| 035 | |a (DE-599)DOAJffbe5213c42e4d77ac6e981b7c1f1287 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QH426-470 | |
| 050 | 0 | |a R723-726 | |
| 100 | 0 | |a Sophie Day |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Past-futures in experimental care: breast cancer and HIV medicine |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developments across other health conditions. We present a 2018–2019 study of experimental breast cancer care in an urban clinical setting in the light of two other studies in the same hospital group: in the same cancer service (2013–14) and, prompted by these earlier findings, an interview study in HIV services (2014–15). We found that patients and staff anticipated better outcomes by treating sub-types of breast cancer but they also hoped for a better one-size-fits-all approach, akin to the antiretroviral treatments introduced for HIV and explored in our interview study. We conclude that the promise of targeted treatment for sub-types of disease – variously described as experimental care, personalised, precision, stratified and sub-group medicine – is accompanied by hopes for a single, standard, effective approach. | ||
| 650 | 4 | |a experimental | |
| 650 | 4 | |a care | |
| 650 | 4 | |a medicine | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a hiv | |
| 653 | 0 | |a Genetics | |
| 653 | 0 | |a Medical philosophy. Medical ethics | |
| 700 | 0 | |a William Viney |e verfasserin |4 aut | |
| 700 | 0 | |a Jane Bruton |e verfasserin |4 aut | |
| 700 | 0 | |a Helen Ward |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t New Genetics and Society |d Taylor & Francis Group, 2023 |g 40(2021), 4, Seite 449-472 |w (DE-627)DOAJ000157228 |x 14699915 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2021 |g number:4 |g pages:449-472 |
| 856 | 4 | 0 | |u https://doi.org/10.1080/14636778.2020.1861542 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ffbe5213c42e4d77ac6e981b7c1f1287 |z kostenfrei |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14636778.2020.1861542 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1463-6778 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1469-9915 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2021 |e 4 |h 449-472 | ||
| author_variant |
s d sd w v wv j b jb h w hw |
|---|---|
| matchkey_str |
article:14699915:2021----::atuueieprmnacrbescn |
| hierarchy_sort_str |
2021 |
| callnumber-subject-code |
QH |
| publishDate |
2021 |
| allfields |
10.1080/14636778.2020.1861542 doi (DE-627)DOAJ099470578 (DE-599)DOAJffbe5213c42e4d77ac6e981b7c1f1287 DE-627 ger DE-627 rakwb eng QH426-470 R723-726 Sophie Day verfasserin aut Past-futures in experimental care: breast cancer and HIV medicine 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developments across other health conditions. We present a 2018–2019 study of experimental breast cancer care in an urban clinical setting in the light of two other studies in the same hospital group: in the same cancer service (2013–14) and, prompted by these earlier findings, an interview study in HIV services (2014–15). We found that patients and staff anticipated better outcomes by treating sub-types of breast cancer but they also hoped for a better one-size-fits-all approach, akin to the antiretroviral treatments introduced for HIV and explored in our interview study. We conclude that the promise of targeted treatment for sub-types of disease – variously described as experimental care, personalised, precision, stratified and sub-group medicine – is accompanied by hopes for a single, standard, effective approach. experimental care medicine breast cancer hiv Genetics Medical philosophy. Medical ethics William Viney verfasserin aut Jane Bruton verfasserin aut Helen Ward verfasserin aut In New Genetics and Society Taylor & Francis Group, 2023 40(2021), 4, Seite 449-472 (DE-627)DOAJ000157228 14699915 nnns volume:40 year:2021 number:4 pages:449-472 https://doi.org/10.1080/14636778.2020.1861542 kostenfrei https://doaj.org/article/ffbe5213c42e4d77ac6e981b7c1f1287 kostenfrei http://dx.doi.org/10.1080/14636778.2020.1861542 kostenfrei https://doaj.org/toc/1463-6778 Journal toc kostenfrei https://doaj.org/toc/1469-9915 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 40 2021 4 449-472 |
| spelling |
10.1080/14636778.2020.1861542 doi (DE-627)DOAJ099470578 (DE-599)DOAJffbe5213c42e4d77ac6e981b7c1f1287 DE-627 ger DE-627 rakwb eng QH426-470 R723-726 Sophie Day verfasserin aut Past-futures in experimental care: breast cancer and HIV medicine 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developments across other health conditions. We present a 2018–2019 study of experimental breast cancer care in an urban clinical setting in the light of two other studies in the same hospital group: in the same cancer service (2013–14) and, prompted by these earlier findings, an interview study in HIV services (2014–15). We found that patients and staff anticipated better outcomes by treating sub-types of breast cancer but they also hoped for a better one-size-fits-all approach, akin to the antiretroviral treatments introduced for HIV and explored in our interview study. We conclude that the promise of targeted treatment for sub-types of disease – variously described as experimental care, personalised, precision, stratified and sub-group medicine – is accompanied by hopes for a single, standard, effective approach. experimental care medicine breast cancer hiv Genetics Medical philosophy. Medical ethics William Viney verfasserin aut Jane Bruton verfasserin aut Helen Ward verfasserin aut In New Genetics and Society Taylor & Francis Group, 2023 40(2021), 4, Seite 449-472 (DE-627)DOAJ000157228 14699915 nnns volume:40 year:2021 number:4 pages:449-472 https://doi.org/10.1080/14636778.2020.1861542 kostenfrei https://doaj.org/article/ffbe5213c42e4d77ac6e981b7c1f1287 kostenfrei http://dx.doi.org/10.1080/14636778.2020.1861542 kostenfrei https://doaj.org/toc/1463-6778 Journal toc kostenfrei https://doaj.org/toc/1469-9915 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 40 2021 4 449-472 |
| allfields_unstemmed |
10.1080/14636778.2020.1861542 doi (DE-627)DOAJ099470578 (DE-599)DOAJffbe5213c42e4d77ac6e981b7c1f1287 DE-627 ger DE-627 rakwb eng QH426-470 R723-726 Sophie Day verfasserin aut Past-futures in experimental care: breast cancer and HIV medicine 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developments across other health conditions. We present a 2018–2019 study of experimental breast cancer care in an urban clinical setting in the light of two other studies in the same hospital group: in the same cancer service (2013–14) and, prompted by these earlier findings, an interview study in HIV services (2014–15). We found that patients and staff anticipated better outcomes by treating sub-types of breast cancer but they also hoped for a better one-size-fits-all approach, akin to the antiretroviral treatments introduced for HIV and explored in our interview study. We conclude that the promise of targeted treatment for sub-types of disease – variously described as experimental care, personalised, precision, stratified and sub-group medicine – is accompanied by hopes for a single, standard, effective approach. experimental care medicine breast cancer hiv Genetics Medical philosophy. Medical ethics William Viney verfasserin aut Jane Bruton verfasserin aut Helen Ward verfasserin aut In New Genetics and Society Taylor & Francis Group, 2023 40(2021), 4, Seite 449-472 (DE-627)DOAJ000157228 14699915 nnns volume:40 year:2021 number:4 pages:449-472 https://doi.org/10.1080/14636778.2020.1861542 kostenfrei https://doaj.org/article/ffbe5213c42e4d77ac6e981b7c1f1287 kostenfrei http://dx.doi.org/10.1080/14636778.2020.1861542 kostenfrei https://doaj.org/toc/1463-6778 Journal toc kostenfrei https://doaj.org/toc/1469-9915 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 40 2021 4 449-472 |
| allfieldsGer |
10.1080/14636778.2020.1861542 doi (DE-627)DOAJ099470578 (DE-599)DOAJffbe5213c42e4d77ac6e981b7c1f1287 DE-627 ger DE-627 rakwb eng QH426-470 R723-726 Sophie Day verfasserin aut Past-futures in experimental care: breast cancer and HIV medicine 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developments across other health conditions. We present a 2018–2019 study of experimental breast cancer care in an urban clinical setting in the light of two other studies in the same hospital group: in the same cancer service (2013–14) and, prompted by these earlier findings, an interview study in HIV services (2014–15). We found that patients and staff anticipated better outcomes by treating sub-types of breast cancer but they also hoped for a better one-size-fits-all approach, akin to the antiretroviral treatments introduced for HIV and explored in our interview study. We conclude that the promise of targeted treatment for sub-types of disease – variously described as experimental care, personalised, precision, stratified and sub-group medicine – is accompanied by hopes for a single, standard, effective approach. experimental care medicine breast cancer hiv Genetics Medical philosophy. Medical ethics William Viney verfasserin aut Jane Bruton verfasserin aut Helen Ward verfasserin aut In New Genetics and Society Taylor & Francis Group, 2023 40(2021), 4, Seite 449-472 (DE-627)DOAJ000157228 14699915 nnns volume:40 year:2021 number:4 pages:449-472 https://doi.org/10.1080/14636778.2020.1861542 kostenfrei https://doaj.org/article/ffbe5213c42e4d77ac6e981b7c1f1287 kostenfrei http://dx.doi.org/10.1080/14636778.2020.1861542 kostenfrei https://doaj.org/toc/1463-6778 Journal toc kostenfrei https://doaj.org/toc/1469-9915 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 40 2021 4 449-472 |
| allfieldsSound |
10.1080/14636778.2020.1861542 doi (DE-627)DOAJ099470578 (DE-599)DOAJffbe5213c42e4d77ac6e981b7c1f1287 DE-627 ger DE-627 rakwb eng QH426-470 R723-726 Sophie Day verfasserin aut Past-futures in experimental care: breast cancer and HIV medicine 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developments across other health conditions. We present a 2018–2019 study of experimental breast cancer care in an urban clinical setting in the light of two other studies in the same hospital group: in the same cancer service (2013–14) and, prompted by these earlier findings, an interview study in HIV services (2014–15). We found that patients and staff anticipated better outcomes by treating sub-types of breast cancer but they also hoped for a better one-size-fits-all approach, akin to the antiretroviral treatments introduced for HIV and explored in our interview study. We conclude that the promise of targeted treatment for sub-types of disease – variously described as experimental care, personalised, precision, stratified and sub-group medicine – is accompanied by hopes for a single, standard, effective approach. experimental care medicine breast cancer hiv Genetics Medical philosophy. Medical ethics William Viney verfasserin aut Jane Bruton verfasserin aut Helen Ward verfasserin aut In New Genetics and Society Taylor & Francis Group, 2023 40(2021), 4, Seite 449-472 (DE-627)DOAJ000157228 14699915 nnns volume:40 year:2021 number:4 pages:449-472 https://doi.org/10.1080/14636778.2020.1861542 kostenfrei https://doaj.org/article/ffbe5213c42e4d77ac6e981b7c1f1287 kostenfrei http://dx.doi.org/10.1080/14636778.2020.1861542 kostenfrei https://doaj.org/toc/1463-6778 Journal toc kostenfrei https://doaj.org/toc/1469-9915 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 40 2021 4 449-472 |
| language |
English |
| source |
In New Genetics and Society 40(2021), 4, Seite 449-472 volume:40 year:2021 number:4 pages:449-472 |
| sourceStr |
In New Genetics and Society 40(2021), 4, Seite 449-472 volume:40 year:2021 number:4 pages:449-472 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
experimental care medicine breast cancer hiv Genetics Medical philosophy. Medical ethics |
| isfreeaccess_bool |
true |
| container_title |
New Genetics and Society |
| authorswithroles_txt_mv |
Sophie Day @@aut@@ William Viney @@aut@@ Jane Bruton @@aut@@ Helen Ward @@aut@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
DOAJ000157228 |
| id |
DOAJ099470578 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ099470578</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414034738.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1080/14636778.2020.1861542</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ099470578</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJffbe5213c42e4d77ac6e981b7c1f1287</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH426-470</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R723-726</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sophie Day</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Past-futures in experimental care: breast cancer and HIV medicine</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developments across other health conditions. We present a 2018–2019 study of experimental breast cancer care in an urban clinical setting in the light of two other studies in the same hospital group: in the same cancer service (2013–14) and, prompted by these earlier findings, an interview study in HIV services (2014–15). We found that patients and staff anticipated better outcomes by treating sub-types of breast cancer but they also hoped for a better one-size-fits-all approach, akin to the antiretroviral treatments introduced for HIV and explored in our interview study. We conclude that the promise of targeted treatment for sub-types of disease – variously described as experimental care, personalised, precision, stratified and sub-group medicine – is accompanied by hopes for a single, standard, effective approach.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">experimental</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">care</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hiv</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Genetics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical philosophy. Medical ethics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">William Viney</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jane Bruton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helen Ward</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">New Genetics and Society</subfield><subfield code="d">Taylor & Francis Group, 2023</subfield><subfield code="g">40(2021), 4, Seite 449-472</subfield><subfield code="w">(DE-627)DOAJ000157228</subfield><subfield code="x">14699915</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:40</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:449-472</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1080/14636778.2020.1861542</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ffbe5213c42e4d77ac6e981b7c1f1287</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1080/14636778.2020.1861542</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1463-6778</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1469-9915</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">40</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="h">449-472</subfield></datafield></record></collection>
|
| callnumber-first |
Q - Science |
| author |
Sophie Day |
| spellingShingle |
Sophie Day misc QH426-470 misc R723-726 misc experimental misc care misc medicine misc breast cancer misc hiv misc Genetics misc Medical philosophy. Medical ethics Past-futures in experimental care: breast cancer and HIV medicine |
| authorStr |
Sophie Day |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)DOAJ000157228 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
QH426-470 |
| illustrated |
Not Illustrated |
| issn |
14699915 |
| topic_title |
QH426-470 R723-726 Past-futures in experimental care: breast cancer and HIV medicine experimental care medicine breast cancer hiv |
| topic |
misc QH426-470 misc R723-726 misc experimental misc care misc medicine misc breast cancer misc hiv misc Genetics misc Medical philosophy. Medical ethics |
| topic_unstemmed |
misc QH426-470 misc R723-726 misc experimental misc care misc medicine misc breast cancer misc hiv misc Genetics misc Medical philosophy. Medical ethics |
| topic_browse |
misc QH426-470 misc R723-726 misc experimental misc care misc medicine misc breast cancer misc hiv misc Genetics misc Medical philosophy. Medical ethics |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
New Genetics and Society |
| hierarchy_parent_id |
DOAJ000157228 |
| hierarchy_top_title |
New Genetics and Society |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)DOAJ000157228 |
| title |
Past-futures in experimental care: breast cancer and HIV medicine |
| ctrlnum |
(DE-627)DOAJ099470578 (DE-599)DOAJffbe5213c42e4d77ac6e981b7c1f1287 |
| title_full |
Past-futures in experimental care: breast cancer and HIV medicine |
| author_sort |
Sophie Day |
| journal |
New Genetics and Society |
| journalStr |
New Genetics and Society |
| callnumber-first-code |
Q |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
449 |
| author_browse |
Sophie Day William Viney Jane Bruton Helen Ward |
| container_volume |
40 |
| class |
QH426-470 R723-726 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sophie Day |
| doi_str_mv |
10.1080/14636778.2020.1861542 |
| author2-role |
verfasserin |
| title_sort |
past-futures in experimental care: breast cancer and hiv medicine |
| callnumber |
QH426-470 |
| title_auth |
Past-futures in experimental care: breast cancer and HIV medicine |
| abstract |
Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developments across other health conditions. We present a 2018–2019 study of experimental breast cancer care in an urban clinical setting in the light of two other studies in the same hospital group: in the same cancer service (2013–14) and, prompted by these earlier findings, an interview study in HIV services (2014–15). We found that patients and staff anticipated better outcomes by treating sub-types of breast cancer but they also hoped for a better one-size-fits-all approach, akin to the antiretroviral treatments introduced for HIV and explored in our interview study. We conclude that the promise of targeted treatment for sub-types of disease – variously described as experimental care, personalised, precision, stratified and sub-group medicine – is accompanied by hopes for a single, standard, effective approach. |
| abstractGer |
Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developments across other health conditions. We present a 2018–2019 study of experimental breast cancer care in an urban clinical setting in the light of two other studies in the same hospital group: in the same cancer service (2013–14) and, prompted by these earlier findings, an interview study in HIV services (2014–15). We found that patients and staff anticipated better outcomes by treating sub-types of breast cancer but they also hoped for a better one-size-fits-all approach, akin to the antiretroviral treatments introduced for HIV and explored in our interview study. We conclude that the promise of targeted treatment for sub-types of disease – variously described as experimental care, personalised, precision, stratified and sub-group medicine – is accompanied by hopes for a single, standard, effective approach. |
| abstract_unstemmed |
Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developments across other health conditions. We present a 2018–2019 study of experimental breast cancer care in an urban clinical setting in the light of two other studies in the same hospital group: in the same cancer service (2013–14) and, prompted by these earlier findings, an interview study in HIV services (2014–15). We found that patients and staff anticipated better outcomes by treating sub-types of breast cancer but they also hoped for a better one-size-fits-all approach, akin to the antiretroviral treatments introduced for HIV and explored in our interview study. We conclude that the promise of targeted treatment for sub-types of disease – variously described as experimental care, personalised, precision, stratified and sub-group medicine – is accompanied by hopes for a single, standard, effective approach. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
4 |
| title_short |
Past-futures in experimental care: breast cancer and HIV medicine |
| url |
https://doi.org/10.1080/14636778.2020.1861542 https://doaj.org/article/ffbe5213c42e4d77ac6e981b7c1f1287 http://dx.doi.org/10.1080/14636778.2020.1861542 https://doaj.org/toc/1463-6778 https://doaj.org/toc/1469-9915 |
| remote_bool |
true |
| author2 |
William Viney Jane Bruton Helen Ward |
| author2Str |
William Viney Jane Bruton Helen Ward |
| ppnlink |
DOAJ000157228 |
| callnumber-subject |
QH - Natural History and Biology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1080/14636778.2020.1861542 |
| callnumber-a |
QH426-470 |
| up_date |
2024-07-03T22:56:53.299Z |
| _version_ |
1803600436452655104 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ099470578</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414034738.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1080/14636778.2020.1861542</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ099470578</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJffbe5213c42e4d77ac6e981b7c1f1287</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH426-470</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R723-726</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sophie Day</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Past-futures in experimental care: breast cancer and HIV medicine</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cambrosio et al. (2018. “Extending Experimentation: Oncology’s Fading Boundary Between Research and Care.” New Genetics and Society 37 (3): 207–226) argue that “experimental care” in contemporary oncology involves the rapid merging of patient research and care, and invite further study into developments across other health conditions. We present a 2018–2019 study of experimental breast cancer care in an urban clinical setting in the light of two other studies in the same hospital group: in the same cancer service (2013–14) and, prompted by these earlier findings, an interview study in HIV services (2014–15). We found that patients and staff anticipated better outcomes by treating sub-types of breast cancer but they also hoped for a better one-size-fits-all approach, akin to the antiretroviral treatments introduced for HIV and explored in our interview study. We conclude that the promise of targeted treatment for sub-types of disease – variously described as experimental care, personalised, precision, stratified and sub-group medicine – is accompanied by hopes for a single, standard, effective approach.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">experimental</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">care</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hiv</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Genetics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical philosophy. Medical ethics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">William Viney</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jane Bruton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helen Ward</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">New Genetics and Society</subfield><subfield code="d">Taylor & Francis Group, 2023</subfield><subfield code="g">40(2021), 4, Seite 449-472</subfield><subfield code="w">(DE-627)DOAJ000157228</subfield><subfield code="x">14699915</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:40</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:449-472</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1080/14636778.2020.1861542</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ffbe5213c42e4d77ac6e981b7c1f1287</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1080/14636778.2020.1861542</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1463-6778</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1469-9915</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">40</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="h">449-472</subfield></datafield></record></collection>
|
| score |
7.3989916 |